Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03394924 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis
A Phase 2 study, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT03394924 is a Phase 2 study that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 68 participants.
The verdict
NCT03394924, a Phase 2 study, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with primary biliary cholangitis
Interventions
- DRUG Placebo
- DRUG EDP-305 1 mg
- DRUG EDP-305 2.5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2017-12-27 |
| Est. Completion | 2020-01-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03394924
The ClinicalTrials.gov registry entry for NCT03394924 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03394924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03394924 about?
NCT03394924 is a clinical study titled "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis". A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with primary biliary cholangitis
What is the current status of trial NCT03394924?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2017-12-27. Estimated completion is 2020-01-16.
What interventions are being tested in trial NCT03394924?
The interventions under investigation include: Placebo (DRUG), EDP-305 1 mg (DRUG), EDP-305 2.5 mg (DRUG).
Who is sponsoring clinical trial NCT03394924?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.